Key Takeaways
- Zoetis has entered a definitive agreement to acquire Neogen’s animal genomics business for $160 million.
- The acquisition includes five international laboratories located in the U.S., Brazil, Australia, China, and the United Kingdom.
- The deal aims to enhance the Zoetis Precision Animal Health portfolio by integrating advanced genotyping and data solutions.
- The transaction is expected to close in the second half of 2026, pending regulatory approvals and customary closing conditions.
- The move expands Zoetis’ capabilities in predictive insights and individualized care for livestock and companion animals.
Strategic Expansion for Zoetis
Zoetis (NYSE: ZTS) announced today that it has signed a definitive agreement to acquire the animal genomics business of Neogen Corporation (NASDAQ: NEOG) for $160 million. This cash transaction is subject to customary closing adjustments and aligns with the company’s long-term strategy to lead livestock innovation through advanced genetic data.
By incorporating Neogen’s genomic technologies, Zoetis intends to broaden its existing Precision Animal Health portfolio. The integration is designed to provide livestock producers and veterinarians with more comprehensive data-driven insights to improve animal productivity and sustainability.
Global Laboratory Infrastructure and Reach
Neogen’s genomics division currently serves a global customer base across 120 countries. The business operates five dedicated laboratories in the United States, Brazil, Australia, China, and the United Kingdom, alongside an office in Canada.
